ETFIQetfiq.com · independent ETF data

GNOM · Global X Genomics & Biotechnology ETF

GNOM holds 50 stocks. 98% of it is not in the S&P 500, and its top ten are 43% of the fund.

Global X · Themes desk · data as of

17.9%Already in the S&P 500
97.6%Active share vs the S&P 500
42.6%Top ten holdings
+75.7%Total return, 1 year

Its ten largest positions

GNOM top ten, 42.6% of the fund, from the holdings filed for May 31, 2026. Source: the fund’s SEC filing.
HoldingTickerWeight
GUARDANT HEALTH, INC.5.60%
ILLUMINA, INC.4.83%
NATERA, INC.4.16%
BIOMARIN PHARMACEUTICAL INC.4.09%
ARROWHEAD PHARMACEUTICALS, INC.4.07%
Legend Biotech Corp4.05%
Praxis Precision Medicines Inc4.01%
Twist Bioscience Corp3.97%
VERTEX PHARMACEUTICALS INCORPORATED3.95%
CRISPR Therapeutics AG3.85%

Period by period

GNOM over each window to Sep 4, 2026. Every figure is an ETFIQ calculation. Source: ETFIQ.
WindowTotal returnS&P 500Gap to S&P 500Gap to Nasdaq-100
3 months+32.5%+4.7%+27.8 pts+30.4 pts
6 months+42.3%+15.2%+27.1 pts+22.1 pts
1 year+75.7%+20.0%+55.8 pts+50.1 pts
3 years+46.0%+78.0%−31.9 pts−47.4 pts
Since launch+6.3%+197.5%−191.2 pts−299.5 pts

In plain words

The top ten holdings are 43% of the fund across 50 positions, as filed for May 31, 2026. Over the year to Sep 4, 2026 the fund returned +75.7% with distributions reinvested against +20.0% for the S&P 500, so a holder was ahead by 55.8 pts. It sits 41.5% below its all-time high of Feb 8, 2021.

GNOM (Global X Genomics & Biotechnology ETF), themes desk fields as of Sep 4, 2026. Source: ETFIQ.
Theme (ETFIQ, editorial)Genomics and biotech innovation
LaunchedApr 10, 2019
Already in the S&P 500, by weight (ETFIQ)17.9%
Active share vs the S&P 500 (ETFIQ)97.6%
Already in the Nasdaq-100, by weight (ETFIQ)5.9%
Active share vs the Nasdaq-100 (ETFIQ)98.8%
Top ten holdings weight42.6%
Holdings50
Holdings as of (SEC N-PORT)May 31, 2026
Top holdingsGUARDANT HEALTH, INC. 5.6%, ILLUMINA, INC. 4.8%, NATERA, INC. 4.2%, BIOMARIN PHARMACEUTICAL INC. 4.1%, ARROWHEAD PHARMACEUTICALS, INC. 4.1%, Legend Biotech Corp 4.0%, Praxis Precision Medicines Inc 4.0%, Twist Bioscience Corp 4.0%, VERTEX PHARMACEUTICALS INCORPORATED 4.0%, CRISPR Therapeutics AG 3.9%
Net assets (SEC filing, whole fund, as filed for May 31, 2026)$56m
Below its all-time high (ETFIQ)−41.5%
Expense ratio (prospectus XBRL)0.50%
Fee for the part that differs from the S&P 500, active expense ratio (ETFIQ)0.51%
Closest funds by holdings overlapARKG 37%, HELX 30%, EKG 25%, HTEC 22%, IDNA 20%

Holdings from the fund’s latest public SEC N-PORT filing; overlap and active share computed by ETFIQ against the IVV and QQQM books; returns from Tiingo end-of-day prices with distributions reinvested. How this desk computes every figure

Questions people ask

How much of GNOM is already in the S&P 500?
By its holdings filed for May 31, 2026, 18% of GNOM by weight is stocks the S&P 500 already holds. Its active share against the index is 98%, so that share is the part doing something different.
What does GNOM hold?
50 positions as filed for May 31, 2026, with the top ten at 43% of the fund. The largest are GUARDANT HEALTH, INC. at 5.6%, ILLUMINA, INC. at 4.8%, NATERA, INC. at 4.2%.
Has GNOM beaten the S&P 500?
Over the year to Sep 4, 2026 GNOM returned +75.7% with distributions reinvested, against +20.0% for the S&P 500, so it finished ahead of the index by 55.8 points.
What does GNOM cost?
The prospectus expense ratio is 0.50% a year. Because 98% of the fund differs from the S&P 500, the fee on that differing part works out at 0.51%.

The words on this page

Active share
The part of the fund doing something the index is not, as a percentage. It is the part a fee is actually buying.
Weight overlap
The share of money two portfolios hold in the same securities at the same weight. Above 50%, holding both is close to holding one of them twice.
Already in the index
The fund’s weight in securities the S&P 500 holds at all. A fund can be made entirely of index names and still have high active share, because it holds them at very different weights.
Top ten
What the ten largest positions add up to. The higher it is, the more the fund is a bet on a few companies rather than a theme.

Every term this desk uses, defined in full on the themes desk vocabulary page.

Where these figures came from

ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.

Funds near this one

Put this on your own page

The difference bar for GNOM, redrawn every trading night. Free to use with the credit link; paste these two lines into any page or newsletter.

GNOM difference bar, ETFIQ

<a href="https://etfiq.com/funds/GNOM.html"><img src="https://etfiq.com/embed/themes/GNOM.svg" alt="GNOM difference bar, ETFIQ" width="640"></a>
<p><a href="https://etfiq.com/funds/GNOM.html">GNOM difference bar, updated daily by ETFIQ</a></p>
GNOM on the themes desk, ETFIQ, data as of Sep 4, 2026. Every figure is arithmetic on a named public source; the method is at etfiq.com/methodology. ETFIQ is an independent publisher, is not a fund issuer, broker-dealer or investment adviser, and makes no recommendations.
Use this data, or open the live card

Open GNOM on the live ETFIQ desk, where the figures update as the desk refreshes.

Cite this page. ETFIQ, GNOM on the themes desk, data as of Sep 4, 2026. https://etfiq.com/funds/GNOM.html Free to use with attribution; the underlying files are at Open data.

How this desk computes every figure · Standards and sources